The global end-stage kidney disease treatment market is anticipated to grow at considerable CAGR during the forecast period (2022-2028). Key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in January 2019, Fresenius Medical Care has launched a 4008A dialysis machine. The purpose of the launch was to improve the accessibility of high-standard dialysis treatment to patients who are suffering from end-stage kidney diseases with high-standard therapies while reducing the cost of health care systems. In February 2019, B-Braun acquired NxSatg’s bloodline business. Through this acquisition, B-Braun aimed to expand its portfolio in the bloodline business by further strengthening its position in the market. Additionally, in 2019 AWAK Technologies manufactured a portable peritoneal dialysis device. Food and Drug Administration (FDA) has approved the product for use by end-stage kidney disease patients. According to the clinical trial of AWAK’s portable peritoneal dialysis device conducted at Singapore General Hospital, the device efficiently removed the accumulations of toxins from the body.
Browse the full report description of “End-Stage Kidney Disease Treatment Market Size, Share & Trends by Diagnosis (Dialysis and Medication and Kidney Transplantation) and by Application (Clinics and Hospitals) Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/end-stage-kidney-disease-treatment-market
Besides, in July 2019, The White House and the Department of Health and Human Services has launched Advancing American Kidney Health Initiative. The initiative aimed to prevent kidney failure through better treatment and diagnosis. In July 2019, Baxter International Inc. also collaborated with Advancing American Kidney Health Initiative. The company invested in the initiative to support the implementation of manufacturing capacity. The investments was aimed at making and distributing the Peritoneal Dialysis solutions, devices, and cassettes.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type of treatment
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- BLR Bio LLC, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd, CTI BioPharma Corp, and more.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global End-Stage Kidney Disease Treatment Market Report Segment
By Type of Treatment
• Dialysis
• Medication and Kidney Transplantation
By Application
• Clinics
• Hospitals
Global End-Stage Kidney Disease Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/end-stage-kidney-disease-treatment-market